Aduro Biotech (ADRO) : The money flow analysis of Aduro Biotech (ADRO) indicates a $0.39 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $1.53 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 3.94 and so was the total money flow at $1.14 million. The bulls lapped up $1.06 million worth of block trades on upticks. The money flow was $1.06 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Aduro Biotech (ADRO), pushing it down by -0.04% for the day. The stock slid $0.01 and traded at $14.22 during the day. Nonetheless, the stock is 6.16% over the previous weeks close.
The company Insiders own 6.5% of Aduro Biotech shares according to the proxy statements. Institutional Investors own 29.83% of Aduro Biotech shares. During last six month period, the net percent change held by insiders has seen a change of -4.24%.
In a related news,The officer (Chief Scientific Officer) of Aduro Biotech, Inc., Dubensky Thomas W. sold 25,000 shares at $14.03 on September 1, 2016. The Insider selling transaction had a total value worth of $350,750. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Aduro Biotech (NASDAQ:ADRO): The stock opened at $14.28 and touched an intraday high of $14.5 on Friday. During the day, the stock corrected to an intraday low of $13.976, however, the bulls stepped in and pushed the price higher to close in the green at $14.49 with a gain of 1.90% for the day. The total traded volume for the day was 539,187. The stock had closed at $14.22 in the previous trading session.
Aduro Biotech (ADRO) has been under a strong bear grip, hence the stock is down -6.69% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.67% in the past 1 week. The stock has risen by 8.22% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.82% in the past 4 weeks.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduros first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.